Multi-omics analysis of primary aldosteronism
Official title: Multi-omics Studies of Primary Aldosteronism
Run by Peking University First Hospital · NCT07111351 · Data updated 2026-11-12
This study will test whether multi-omics profiling of people with primary aldosteronism, people with primary hypertension, and healthy volunteers can find biological markers that improve diagnosis and subtyping.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 400 (estimated) |
| Sponsor | Peking University First Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | August 15, 2025 |
| Main results expected | April 1, 2029 |
| Study ends | May 31, 2029 |
| Registry record updated | December 9, 2025 |
| Trial ID | NCT07111351 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–80 with a diagnosis of primary aldosteronism or primary hypertension, or age- and sex-matched healthy volunteers with complete medical records who can give informed consent are ideal candidates.
✕Probably not a fit
People with prior adrenal-region chemotherapy or radiotherapy, active HIV/hepatitis B/C infection, known malignancy or autoimmune disease, or those who withdraw consent are excluded and may not receive benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers will collect clinical data and biological samples from adults with primary aldosteronism, adults with primary hypertension, and age- and sex-matched healthy controls to perform integrated multi-omics analyses (for example genomics, transcriptomics, proteomics, and metabolomics). Clinical information will include diagnostic measures such as aldosterone-to-renin ratios, confirmatory testing results, and subtype differentiation data when available. The project aims to link molecular signatures with clinical phenotypes to identify biomarkers that could simplify diagnosis and clarify whether a patient has unilateral or bilateral disease. Data will be generated and analyzed at Peking University First Hospital with comparison across the three participant groups.
Why it matters
Potential benefit: If successful, this could lead to earlier and more accurate diagnosis and more personalized treatment choices for people with primary aldosteronism.
How similar studies have gone: Prior genomic and transcriptomic work in primary aldosteronism has identified driver mutations and molecular signatures, but fully integrated multi-omics approaches are still emerging and not yet widely established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Diagnosed with primary aldosteronism , primary hypertension , or age- and sex-matched healthy controls; 2. Aged 18-80 years with complete medical records; 3. Willing to participate voluntarily and provide informed consent. Exclusion Criteria: 1. History of chemotherapy or radiotherapy in the adrenal region ; 2. Positive serological or nucleic acid test results for HIV, hepatitis B, or hepatitis C , or a prior confirmed diagnosis; 3. Individuals with malignancies or autoimmune disorders ; 4. Study withdrawal during the trial period
Where it's running
-
Peking University First Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: Wencong Han
- Email: hanwencong163@163.com
- Phone: +8618863665375
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Kidney stiffness measured by ultrasound in hypertension and healthy volunteers
This study tests whether kidney stiffness measured by a non-invasive ultrasound method differs between people with high blood pressure and healthy individuals.
-
Inclisiran vs. Statin for Primary Aldosteronism
This trial tests whether inclisiran plus amlodipine works differently from a statin-based approach in people with primary aldosteronism and high blood pressure.
-
Left-atrial Fibrosis in Persistent Atrial Fibrillation and Its Comorbidities
This study tests how comorbid conditions like sleep apnea and primary aldosteronism relate to left-atrial fibrosis and AF recurrence in patients undergoing ablation.
-
Metomidate PET-CT vs Usual Care for Primary Aldosteronism
This study tests whether [11C] metomidate PET-CT can help orient treatment for people with primary aldosteronism compared with the usual adrenal venous sampling approach.
-
Captopril Test with LC-MS/MS for Aldosterone and Renin in Primary Aldosteronism
This study tests whether measuring aldosterone with LC-MS/MS during a captopril test can better diagnose primary aldosteronism.
-
Finerenone vs. Spironolactone for Primary Aldosteronism
This trial tests whether finerenone works as well as spironolactone to lower blood pressure and improve related health measures in adults with primary aldosteronism.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.